ArticleGland surgery2025
Correlation between ultrasound-based hepatic steatosis grade and thyroid hormone levels.
Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid hormones impact on metabolic homeostasis, and low thyroid hormone levels, both systemically and hepatically, have been linked to hepatic steatosis. However, prior studies in this area often lacked quantification of steatosis. Ultrasound attenuation analysis (USAT) is a novel imaging technique for hepatic steatosis detection based on the attenuation coefficient. Our objective in this study was to assess the correlation between thyroid hormone levels and hepatic steatosis via the USAT attenuation coefficient in metabolic dysfunction-associated steatotic liver disease (MASLD) and chronic hepatitis B (CHB) groups. Methods: This retrospective study included 86 patients with CHB and 45 patients with suspicious MASLD. Demographic information, biochemical parameters, and thyroid hormone levels were analyzed. The severity of steatosis in MASLD or CHB was assessed by USAT. Results: Patients in the MASLD group were more likely to have type 2 diabetes mellitus (T2DM) and hypertension as compared with those in the CHB group (P<0.05). The levels of triiodothyronine (T3) were significantly lower and the platelet counts higher in the MASLD group than in the CHB group (P<0.05). The body mass index (BMI), distance from skin to capsule, USAT values, and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in patients with hepatic steatosis were significantly higher than those in patients without hepatic steatosis (P<0.05). Logistic regression analysis indicated a correlation between free triiodothyronine (FT3) level and hepatic steatosis (P=0.04) as well as between free thyroxine (FT4) level and hepatic steatosis (P=0.045). Conclusions: Quantitative USAT evaluation suggested that hepatic steatosis is strongly correlated with thyroid hormones. These data emphasize the relevance of thyroid hormones for regulating hepatic lipid accumulation and metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.